BioSpace News Archive

Deals

Aduro and Chinook to Merge, Launch New Clinical Trials for their Pipeline

When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.

June 2, 2020
·
3 min read
·
Krystle Vermes
Business

FDA Commissioner Outlines Plans to Improve FDA Post-Pandemic

U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn recently gave a speech to the Alliance for a Stronger FDA. In it, he suggested that some of the changes forced on the agency by the COVID-19 pandemic are likely to become permanent.

June 2, 2020
·
5 min read
·
Mark Terry
Business

Emergent BioSolutions Joins Operation Warp Speed for COVID-19 Vaccine Development

Emergent BioSolutions, a contract development and manufacturing organization, announced it had signed a public-private partnership under Operation Warp Speed worth about $628 million.

June 2, 2020
·
4 min read
·
Mark Terry
BioCapital

CSL Behring Takes Multiple Shots at COVID-19

CSL Behring has developed a number of strategies to address COVID-19, the disease caused by the novel coronavirus that originated in China and spread across the globe in a matter of months.

June 2, 2020
·
4 min read
·
Alex Keown
Drug Development

After Failure of Earache Drug, Novus Therapeutics Seeks Strategic Alternatives

Novus Therapeutics announced that its Phase IIa clinical trial of OPO201 in acute otitis media, or inflammation of the middle ear, failed to meet its primary endpoint.

June 2, 2020
·
3 min read
·
Mark Terry
Drug Development

BMS’ Recently Approved MS Drug, Zeposia, Shows Promise in Ulcerative Colitis Study

This morning, BMS said Zeposia achieved positive topline results in the Phase III True North clinical study in patients with moderate to severe ulcerative colitis.

June 2, 2020
·
2 min read
·
Alex Keown
Pharm Country

Pfizer Establishes $500 Million Fund to Invest in Publicly-Traded Biotechs

Pfizer has its eye on supporting innovation in the biotech industry to support small and medium-sized companies working in indications that fall under Pfizer’s core areas of focus.

June 2, 2020
·
2 min read
·
Alex Keown
Business

Biopharma Update on the Novel Coronavirus: June 2

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.

June 2, 2020
·
4 min read
·
BioSpace Editorial Staff
Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that dosing has commenced in the UK Government-backed Phase II clinical trial assessing bemcentinib in hospitalised COVID-19 patients.

June 2, 2020
·
4 min read
Business

Mission Moves to New Babraham Campus Headquarters

Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes, announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge, UK.

June 2, 2020
·
3 min read